Our products

eConsent

Ease of understanding for patients. Full visibility and automated control over the consent process for sponsors. Extend your clinical trial command and control center with Suvoda eConsent.

Patients
53%

Only 53% of patients understand the potential for placebos in clinical research from informed consent documents i

Amendments
3+

Protocols with 3+ amendments add 3 weeks to planned treatment duration, on average i

January/February 2022 Impact Report, Tufts Center for the Study of Drug Development.
Visibility
100%

Experience 100% visibility over consent and reconsent at all sites and for all patients

A PATIENT-CRITICAL PROCESS

Reduce regulatory risk, administrative burdens, and study duration and expenses, created by mid-trial consent requirements.

In today’s complex clinical studies, informed consent isn’t just a first step in a patient’s clinical trial journey. It’s a process that must be repeated along the way, as the vast majority of protocol amendments require the patients to re-consent. The result is heightened risk of regulatory non-compliance, heavier administrative burden, and increased study expense and duration. In fact, according to the Tufts Center for the Study of Drug Development, trials with three or more amendments add on average three weeks to treatment duration.

When approximately 70% of the oncology studies we support have at least one protocol amendment, we believe the control and visibility of Suvoda eConsent make it a must-have tool for study and site teams—and their patients.

Watch the video

A PATIENT-CRITICAL PROCESS

Improve patient comprehension. Reduce site burden. And decrease regulatory risk, delays, and expenses created by mid-trial consent requirements.

In today’s clinical studies for novel, life-changing therapeutics, informed consent isn’t just a first step in a patient’s trial journey. It is central to a patient’s understanding of study procedures and is a critical ethical requirement. And it is a process that must be repeated along the way, as the vast majority of protocol amendments require the patients to re-consent. The result is heightened risk of patient misunderstanding, regulatory non-compliance, heavier administrative burden, and increased study expense and duration.

When approximately 70% of the oncology studies we support have at least one protocol amendment, the patient experience and sponsor visibility of Suvoda eConsent make it a must-have tool for study and site teams—and their patients.

OUR PRODUCTS

eConsent

Full visibility and automated control. Extend your clinical trial command and control center with Suvoda’s integrated e-Consent

Trials conducted
900+

with 75% in oncology, rare disease, and CNS

Countries supported
65

with trial sites in thousands of locations

Client satisfaction
9/10

year after year, in our annual company survey

TOOLS FOR PATIENT COMPREHENSION

Powerful features that drive patient understanding and reduce regulatory risk.

Suvoda eConsent features robust functionality that gives patients the tools they need to understand study information, which often includes complex medical and legal terms and concepts. At the same time, the visibility over consent across all study sites and patients means sponsors have control over the full process to minimize delays and reduce the risk of a regulatory finding. 

 
 

Patient comprehension

  • Embedded videos and FAQs

  • In-document discussion threads

  • Cross-linked glossary

Flexible design

  • Electronic signature, wet ink upload, or print-and-sign consent

  • Can accommodate multiple consent types (subject, caregiver, legally authorized representative)

  • Can support multiple, separately timestamped signatures from a participant in a single consent form

  • Multilingual capability

  • Available on multiple devices—web-based, on-site, or patient device

SEAMLESS ARCHITECTURE

Built on our single clinical trial technology platform, Suvoda eConsent and IRT drive automated control. 

To your study and site users, eConsent will simply appear as additional functionality within the Suvoda IRT system. Why? So that data is seamlessly shared, workflows are fully streamlined, and the process is completely controlled. We’ll simply upload your approved consent documents, and whenever a site user begins a study visit, IRT will automatically check in with Suvoda eConsent to confirm that the patient has consented to the latest. If not, a prompt within the IRT drives completion of the consent forms—a matter of just a few clicks within the same digital environment—before the visit is allowed to proceed. 

INTUITIVE INTERFACE

A simple user experience across eConsent and IRT applications - for simplified training and workflow.

Clients have consistently given Suvoda IRT high marks for its minimalist look and feel, intuitive navigation, and patient-centric processes—and ability to drive focus on the immediate task at hand. 

Suvoda eConsent has the same intuitive user interface, managed in the same digital environment as IRT. It enables study and site professionals to calmly and smoothly move from randomization and trial supply management (RTSM) activities to eConsent tasks and back again, without needing to sign onto a new system or significant additional user training. And their ease with the system should help patients find the informed consent process more accessible and understandable. 

INTEGRATED REPORTING

Gain real-time visibility to subjects’ consent status across all your sites, right in the Suvoda IRT system.

We know that if you can’t measure it, you can’t manage it. That’s why Suvoda eConsent maximizes transparency and visibility, compiling critical consent data and presenting it through our robust IRT reporting tools. 

Identify, in real-time, the sites that are lagging in getting patients to consent to the latest versions. Digitally archive consent documents for compliance and audit. With full access to eConsent reports, study teams and field monitors can then take early corrective actions with outlier sites and verify consents were done properly without the need for physical visits. The result? Increased regulatory compliance and reduced risk of excluded patients and discarded data at the end of the trial. 



FEATURED IRT MODULES

At the very first presentation when we saw the system, is it strange to say that it seemed very beautiful? And very easy to use. The flow makes a lot of sense. Users can figure it out. The reports in particular are great, and I can control what I want to see.”
Niv Alon, Head of PMO, Galmed Pharmaceuticals
Related Insights

IRT: The key to wisely-managed patient interactions

A UNIFIED CLINICAL TRIAL PLATFORM

Powering the patient's digital journey in life-changing clinical trials

Embrace today’s clinical trial complexities with a market-leading, real-time software platform to drive confident decisions and calm action.
Client Services

Broad perspective. Keen insight. Calm guidance.

Client Services

Broad perspective. Keen insight. Calm guidance.

Integration

Seamless technology in complex ecosystems

Integration

Seamless technology in complex ecosystems

Request a demo